2. Academic Validation
  3. Bosentan confers cardioprotection against cisplatin toxicity: Involvement of β-arrestin-linked ETA receptor signaling

Bosentan confers cardioprotection against cisplatin toxicity: Involvement of β-arrestin-linked ETA receptor signaling

  • Biochem Pharmacol. 2026 Aug;250(Pt 2):118027. doi: 10.1016/j.bcp.2026.118027.
Hnin Ei Ei Khine 1,  Supachoke Mangmool 2,  Warisara Parichatikanond 3
Affiliations

Affiliations

  • 1 Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
  • 2 Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
  • 3 Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand; Centre of Biopharmaceutical Science for Healthy Ageing, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand; Centre of Molecular Targeting and Integrated Drug Development, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand. Electronic address: [email protected].
PMID: 42069228 DOI: 10.1016/j.bcp.2026.118027
Abstract

The endothelin system, primarily through activation of the endothelin A (ETA) receptor, mediates vasoconstriction and triggers inflammatory and proliferative responses, positioning it as a key mediator and promising therapeutic target in cardiovascular injury. Bosentan, a dual ETA/ETB receptor antagonist, has been reported to act as a biased ligand at the ETA receptor. This study investigated whether bosentan protects H9c2 cardiomyoblasts against cisplatin-induced cardiotoxicity by preferentially modulating β-arrestin-related signaling of ETA receptor. Bosentan treatment suppressed cellular injury by attenuating Reactive Oxygen Species (ROS) production, early Apoptosis, and Caspase-3/7 activity following cisplatin exposure. Bosentan preserved mitochondrial function by improving cellular respiration and glycolysis, as well as upregulating mitochondrial regulators OPA1 and ATP5A and anti-apoptotic BCL2, while downregulating mitochondrial fission-related DNM1 and pro-apoptotic Bax. Co-treatment with endothelin-1 (ET-1) synergistically aggravated cisplatin-induced cellular injury and diminished bosentan-mediated cardioprotection, supporting the involvement of ET receptors. ETA receptor blockade (BQ-123) enhanced bosentan-mediated protection more effectively than ETB receptor inhibition (BQ-788), suggesting ETA receptor dominance. Inhibition of β-arrestin (barbadin) reduced bosentan's efficacy to a greater extent than Gαq protein inhibition (FR900359), highlighting a greater contribution of β-arrestin-mediated pathways. In addition, ERK1/2 and PI3K/Akt inhibition each impaired bosentan-enhanced pro-survival response, indicating the parallel involvement of both survival cascades. Although bosentan antagonizes both ETA and ETB receptors and modulates β-arrestin and Gαq signaling, its protective effect appears primarily mediated by ETA receptor antagonism and β-arrestin-linked pro-survival signaling. This potential mechanism of bosentan may provide a basis for further investigation into therapeutic strategies for chemotherapy-induced cardiotoxicity.

Keywords

Bosentan; Cisplatin; ET(A) receptor; G(αq) protein; Mitochondrial dysfunction; β-arrestin.

Figures
Products